Clinical trial
A Clinical Trial on the Antipsychotic Properties of Cannabidiol
NCT00309413 · University of Cologne, Other · Completed
Key facts
| NCT number | NCT00309413 |
|---|---|
| Title | A Clinical Trial on the Antipsychotic Properties of Cannabidiol |
| Official title | A Placebo-Controlled Randomized Cross-Over Clinical Trial on the Antipsychotic Properties of the Endocannabinoid Modulator Cannabidiol |
| Lead sponsor | University of Cologne, Other |
| Collaborators | Stanley Medical Research Institute Coordinating Centre for Clinical Trials Cologne |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | Placebo/Cannabidiol, Cannabidiol/Placebo |
| Enrollment | 29 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Mar 31, 2006 |
| Last update posted | Jul 25, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: